Effect of Inulin-type Fructose Extracted From Jerusalem Artichoke on Improving Prediabetic State of Type 2 Diabetes

Study on the Mechanisms of Soluble Dietary Fiber Extracted From Jerusalem Artichoke in the Treatment of Pre-type 2 Diabetes

The trial was a multicenter, randomized, double-blind, placebo-controlled, parallel-controlled, exploratory clinical study.Through the intervention of soluble dietary fiber in the pre-type 2 diabetic population, the change of blood glucose spectrum before and after intervention can show the effect of this intervention on the outcome, and further elucidate the effect of soluble dietary fiber intervention on the level of insulin resistance and its effect on outcome. Helps to prevent the more scientific and effective prevention of type 2 diabetes from pre-diabetes.

Subjects who met the criteria were randomly divided into the experimental group and the control group, after 24 weeks of intervention, the incidence of blood sugar reversion to normal was main observed.The main purpose of this study was to investigate the effect of soluble dietary fiber treatment regimens on the conversion rate of pre-type 2 diabetes (converted to normal blood glucose, type 2 diabetes, or stable in the stage of impaired glucose tolerance). The secondary objective was to study the improvement of insulin resistance and changes in intestinal flora after intervention.

Study Overview

Status

Completed

Conditions

Detailed Description

The soluble dietary fiber (NIUCHANG®) and placebo used in the trial were exclusively produced by Inuling (Beijing) Technology Co., Ltd. and provided free of charge. During the treatment period, the treatment group was given oral "NIUCHANG®" (once 15g,once a day)and the control group was given oral placebo (once15 g, once a day) for 24 weeks.

The test was performed for 12 weeks as a course of treatment。At the end of one course of treatment, if the glucose tolerance was changed to normal or the blood glucose was stable in the pre-diabetes phase, the original dose was maintained and continued for 12 weeks. At 24 weeks, patients with normal blood glucose and glucose tolerance tests were followed up for 48 weeks. At the end of one course of treatment, if the blood glucose progresses to the stage of diabetes, the test is withdrawn and treated according to clinical routine.

Study Type

Interventional

Enrollment (Actual)

246

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

The following various situations need to be met at the same time in order to be selected:

  • According to the diagnostic criteria for impaired glucose tolerance in the WHO Diabetes Diagnosis and Classification Standard in 1999: fasting blood glucose ≥6.1mmol/L and <7.0mmol/L, blood glucose 2 hours after oral administration of 75g glucose ≥7.8mmol/L and < 11.1mmol/L;
  • BMI:20kg/㎡ ≤ BMI ≤ 35kg/㎡;
  • Age ≥ 18 and ≤ 70 years old, gender is not limited;
  • Voluntarily participate in the trial and sign the informed consent form.

Exclusion Criteria:

Any of the following circumstances should be excluded and cannot be selected:

  • Acute cardiovascular and cerebrovascular events or myocardial infarction within 6 months;
  • Laboratory examination: liver function AST or ALT ≥ 2.5 × ULN; renal function Cr > 1.2 × ULN;
  • Those with severe gastrointestinal diseases, such as active peptic ulcer, intestinal obstruction, etc.; those who have changed the history of normal structure of the gastrointestinal tract;
  • Hypertensive patients with poor blood pressure control (blood pressure SBP ≥ 160 mmHg and / or DBP ≥ 100 mmHg);
  • Those with severe blood system diseases;
  • Those with other endocrine system diseases, such as hyperthyroidism or hypercortisolism;
  • Those who have a stress state or have secondary blood glucose elevation factors (such as those who take glucocorticoids);
  • Women who are pregnant or breast-feeding, who are planning to be pregnant or who are not willing to contraception during the study;
  • Drug or other drug abusers;
  • Those who may be allergic to the test drug;
  • Those who have participated in other drug trials within 3 months;
  • Those who are unable to cooperate with mental illness;
  • Other circumstances The investigator believes that it is not suitable for the group.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Test group
NIUCHANG(Soluble dietary fiber + prebiotics):Oral, 1 bag (15g) once a day, taking 24 weeks
Placebo Comparator: Control group
Placebo(inactive drug ingredient):Oral, 1 bag (15g) once a day, taking 24 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of blood sugar reversal to normal after intervention
Time Frame: Day 0, Week 24
Through the intervention of soluble dietary fiber in the pre-diabetic population, the change of blood glucose spectrum before and after intervention can show the effect of this intervention on the outcome, and further elucidate the effect of soluble dietary fiber intervention on the level of insulin resistance and its effect on outcome.
Day 0, Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in insulin resistance index
Time Frame: Day 0, Week 24
the incidence of blood sugar reversion to normal was main observed
Day 0, Week 24
Changes in intestinal flora
Time Frame: Day 0, Week1,Week4,Week12,Week 24
If the subject has had diarrhea or taking antibiotics 2 days before and after the fecal specimen should be taken, wait for the stagnation for 1 week before taking the stool specimen to reduce the interference of external factors.
Day 0, Week1,Week4,Week12,Week 24
Incidence of blood glucose stabilization in pre-diabetes after intervention
Time Frame: Day 0, Week12,Week 24
blood glucose becomes stable
Day 0, Week12,Week 24
Incidence of blood glucose progression to diabetes after intervention
Time Frame: Day 0, Week12,Week 24
reduce incidence of blood glucose progression
Day 0, Week12,Week 24
Hemoglobin A1C、Glycated Albumin
Time Frame: Day 0, Week 24
Changes of Hemoglobin A1C and Glycated Albumin.
Day 0, Week 24
The levels of serum insulin
Time Frame: Day 0, Week 24
Insulin levels were measured on an empty stomach, 30 minutes, 60 minutes and 120 minutes after oral administration of 75 g of glucose.
Day 0, Week 24
The levels of serum C-peptid
Time Frame: Day 0, Week 24
C-peptide levels were measured on an empty stomach, 30 minutes, 60 minutes and 120 minutes after oral administration of 75 g of glucose.
Day 0, Week 24
Body weight
Time Frame: Day 0, Week12,Week 24
Changes of body weight.
Day 0, Week12,Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 30, 2016

Primary Completion (Actual)

April 4, 2018

Study Completion (Actual)

April 4, 2018

Study Registration Dates

First Submitted

January 3, 2019

First Submitted That Met QC Criteria

January 3, 2019

First Posted (Actual)

January 4, 2019

Study Record Updates

Last Update Posted (Actual)

January 7, 2019

Last Update Submitted That Met QC Criteria

January 3, 2019

Last Verified

November 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prediabetes

Clinical Trials on Placebo

Subscribe